Phase II Open-Label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis

Trial Profile

Phase II Open-Label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-Infected Patients Receiving Rifampin for Active Tuberculosis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Raltegravir (Primary) ; Efavirenz; Entecavir; Lamivudine; Rifampicin; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms REFLATE TB
  • Most Recent Events

    • 07 Mar 2018 Results (n=153) assessing effects of efavirenz or raltegravir regimens on inflammation and coagulation biomarkers levels up to 48 weeks after ART initiation, in HIV-1 and TB co-infected individuals, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top